Vaginal News and Research

RSS

Tenofovir gel reduces HIV by 39% in women: CAPRISA 004 study

Researchers who conducted a study testing a vaginal microbicide with an antiretroviral (ARV) drug called tenofovir found its use before and after sex was significantly more protective against HIV infection than a placebo gel among women at high risk of HIV. Results of the study, known as CAPRISA 004, are to be reported at the International AIDS Conference (AIDS 2010) in Vienna and published online by the journal Science.

20 Jul 2010

Global Campaign for Microbicides praises CAPRISA 004 gel trial for women's HIV prevention

Results of an advanced clinical trial of an antiretroviral-based microbicide candidate are being announced at the International AIDS Conference in Vienna, Austria. The CAPRISA 004 trial, which tested the safety and effectiveness of 1% tenofovir gel among nearly 900 women at two sites in South Africa, found that using the gel before and after sex provided moderate protection against sexually transmitted HIV.

20 Jul 2010

AVAC applauds CAPRISA 004 microbicide gel trial for preventing sexual transmission of HIV infection

"This is a historic day for HIV prevention research. The CAPRISA 004 results are the first clinical evidence that a microbicide gel can help to prevent sexual transmission of HIV infection," said AVAC Executive Director Mitchell Warren, reacting to the results of the landmark microbicide trial presented today at the International AIDS Conference in Vienna.

20 Jul 2010

Researchers make scientific breakthrough in fight against HIV, genital herpes with a vaginal gel

Researchers have achieved an important scientific breakthrough in the fight against HIV and genital herpes with a vaginal gel that significantly reduces a woman's risk of being infected with these viruses. The results of the ground-breaking safety and effectiveness study of an antiretroviral microbicide gel study were reported today by the Centre for the AIDS Programme of Research in South Africa at the XVIII International AIDS Conference in Vienna, Austria.

20 Jul 2010

New microbicide gel reduces woman's risk of being infected with HIV, genital herpes

Today at the XVIII International AIDS Conference in Vienna, Austria, members of the International Rectal Microbicide Advocates (IRMA) and thousands of other HIV advocates and scientists cheered a long-awaited, much anticipated success in the quest for new HIV prevention technologies. Researchers announced that a vaginal gel has been shown to significantly reduce a woman's risk of being infected with HIV and genital herpes

20 Jul 2010

Infants in African countries receive minimum help to reduce risk of mother-to-child HIV transmission: Study

Only about half of infants born to HIV-infected mothers in some African countries receive a minimum preventive dose of the drug nevirapine to help reduce the risk of mother-to-child HIV transmission, according to a study in the July 21 issue of JAMA, a theme issue on HIV/AIDS.

20 Jul 2010

Starpharma gets FDA nod to start phase 2 bacterial vaginosis study for VivaGel

Starpharma Holdings Limited (ASX:SPL, OTCQX:SPHRY) today announced it had received clearance from the US Food and Drug Administration (FDA) to commence a phase 2 study to investigate VivaGel® for the treatment of bacterial vaginosis (BV).

15 Jul 2010

SeqWright congratulates EraGen on successful FDA 510(k) market clearance of MultiCode-RTx HSV 1 & 2 Kit

EraGen Biosciences Inc., Madison, Wis., was congratulated today by SeqWright, Inc., Houston, on EraGen's successful FDA 510(k) market clearance of its MultiCode-RTx HSV 1 & 2 Kit. This new kit is the first FDA-cleared PCR-based qualitative in vitro diagnostic test for the detection and typing of HSV-1 and HSV-2 from vaginal lesion swab specimens in symptomatic female patients.

13 Jul 2010

Texas Health Presbyterian Hospital Dallas named Center of Excellence for gynecological surgery

Texas Health Presbyterian Hospital Dallas is the first hospital in Texas — and one of only three in the United States — to be named a Center of Excellence for gynecological surgery by the American Institute for Minimally Invasive Surgery.

9 Jul 2010

NOSCAR completes first NOTES transoral and transvaginal gallbladder removal in U.S. human trial

The Natural Orifice Surgery Consortium for Assessment and Research- (NOSCAR-), a joint effort of the American Society for Gastrointestinal Endoscopy (ASGE) and the Society of American Gastrointestinal and Endoscopic Surgeons (SAGES), announces the completion of the first transoral and transvaginal cholecystectomies (gallbladder removal) using Natural Orifice Translumenal Endoscopic Surgery- (NOTES-) in a multicenter human trial in the United States.

From Evident Corporation - Life Sciences 8 Jul 2010

Columbia closes sale of progesterone related assets and 11.2M shares to Watson

Columbia Laboratories, Inc. announced today that it has closed the sale of its progesterone related assets and 11.2 million shares of common stock to Watson Pharmaceuticals, Inc.. Columbia's business now consists of its royalty and manufacturing revenues, potential milestone payments, its collaboration with Watson on the development of next-generation progesterone products, and its novel bioadhesive drug delivery technologies and other products.

6 Jul 2010

Columbia Laboratories' sale of progesterone related assets to Watson receives stockholder approval

Columbia Laboratories, Inc. announced that in a special meeting of stockholders held this morning, stockholders approved the sale of substantially all of Columbia's progesterone related assets to Watson Pharmaceuticals, Inc.. Stockholders also voted to increase the number of authorized shares of Columbia's common stock, $0.01 par value per share, from 100,000,000 to 150,000,000.

2 Jul 2010

Study finds increased neonatal mortality among planned home births

About 1 in 200 women in the US delivers her baby at home, with approximately 75% of these low-risk, single-baby births planned in advance as home deliveries. In a study published online today by the American Journal of Obstetrics & Gynecology (AJOG), researchers from Maine Medical Center, Portland, Maine, analyzed the results of multiple studies from around the world.

1 Jul 2010

Simbionix, USF Health receive BIRD Grant for development of Laparoscopic Hysterectomy simulation module

Simbionix Ltd., a subsidiary of Simbionix USA Corporation, the world's leading provider of medical education and simulation training products for medical professionals and the healthcare industry, and USF Health, an organization dedicated to creating a model of health care based on understanding the full spectrum of health, are proud to announce that together they received a BIRD (Binational Industrial Research and Development) Grant to support the development of a Laparoscopic Hysterectomy simulation module.

1 Jul 2010

Complication rates for vaginal and C-section deliveries can vary across hospitals

Complication rates for vaginal and C-section deliveries can vary widely from one hospital to the next according to a study released today by HealthGrades, the leading independent health care ratings organization.

30 Jun 2010

Seventh Annual HealthGrades Maternity Care in Hospitals Study ranks Good Samaritan in top 5%

Good Samaritan Hospital's maternity care is in the top 5 percent in the nation for the third year in a row according to a new study issued today by HealthGrades, Inc., the independent ratings organization. The Seventh Annual HealthGrades Maternity Care in Hospitals Study used state-government data to compare hospitals in terms of complication rates for vaginal and C-section deliveries as well as neonatal mortality.

30 Jun 2010

FDA grants Abbott 510(k) clearance to market molecular diagnostic test for detection of chlamydia, gonorrhea

Abbott announced today that it has received 510(k) clearance from the U.S. Food and Drug Administration to market a new, sensitive molecular diagnostic test and instrument to simultaneously detect two of the nation's most prevalent sexually transmitted diseases (STDs), gonorrhea and chlamydia, including a new variant strain of chlamydia recently discovered in Sweden.

28 Jun 2010

Florida obstetricians collaborate to lower premature and Cesarean birth rates

Much has been published of late, in medical journals as well as in the general media, concerning the national rise in both the Cesarean section and premature birth rates. While not directly connected, the two medical concerns have many interrelated variables. Nationally, the Cesarean section rate has risen to 32 percent of all births, while the rate of premature birth has climbed to just over 12 percent.

24 Jun 2010

Research findings support the need to establish standards for DFSA care

New toxicology findings reveal the presence of drugs and/or alcohol in 76 per cent of women and men who suspect they were victims of drug-facilitated sexual assault. Of those, 64 per cent did not report voluntarily consuming the drugs found, supporting their belief that they may have been slipped a drug. In addition, unexpected male DNA was found in a substantial number of cases, confirming sexual activity.

19 Jun 2010

Synthetic sutures less painful than natural "catgut" sutures after vaginal birth

Synthetic sutures appear to cause less pain than natural "catgut" sutures in women who receive stitches after a vaginal birth, according to a new review of studies.

16 Jun 2010

Vaginal News and Research

Tenofovir gel reduces HIV by 39% in women: CAPRISA 004 study

Global Campaign for Microbicides praises CAPRISA 004 gel trial for women's HIV prevention

AVAC applauds CAPRISA 004 microbicide gel trial for preventing sexual transmission of HIV infection

Researchers make scientific breakthrough in fight against HIV, genital herpes with a vaginal gel

New microbicide gel reduces woman's risk of being infected with HIV, genital herpes

Infants in African countries receive minimum help to reduce risk of mother-to-child HIV transmission: Study

Starpharma gets FDA nod to start phase 2 bacterial vaginosis study for VivaGel

SeqWright congratulates EraGen on successful FDA 510(k) market clearance of MultiCode-RTx HSV 1 & 2 Kit

Texas Health Presbyterian Hospital Dallas named Center of Excellence for gynecological surgery

NOSCAR completes first NOTES transoral and transvaginal gallbladder removal in U.S. human trial

Columbia closes sale of progesterone related assets and 11.2M shares to Watson

Columbia Laboratories' sale of progesterone related assets to Watson receives stockholder approval

Study finds increased neonatal mortality among planned home births

Simbionix, USF Health receive BIRD Grant for development of Laparoscopic Hysterectomy simulation module

Complication rates for vaginal and C-section deliveries can vary across hospitals

Seventh Annual HealthGrades Maternity Care in Hospitals Study ranks Good Samaritan in top 5%

FDA grants Abbott 510(k) clearance to market molecular diagnostic test for detection of chlamydia, gonorrhea

Florida obstetricians collaborate to lower premature and Cesarean birth rates

Research findings support the need to establish standards for DFSA care

Synthetic sutures less painful than natural "catgut" sutures after vaginal birth

Industry Focus eBook - Analytical Chemistry (2nd Edition) eBook

Advancing Intracellular Delivery with LumiPore®

How ELRIG Is Helping Mid-Career Scientists Navigate Leadership, Career Change and Redundancy

The role of UV-Vis in biopharma QC

Latest News